Abstract
Angiotensin Converting Enzyme (ACE) regulates blood pressure and electrolyte balance by converting angiotensin I into angiotensin II, which acts as vasoconstrictor and aldosterone-stimulating peptide. ACE is also known to inactivate vasodilators, bradykinin and angiotensin 1–7 peptide. Thus, the down-regulation of ACE activity would be very beneficial in various cardiovascular diseases. In present in silico approach, virtual screening was performed to identify possible novel inhibitors of testis ACE (tACE) from ZINC database using Dockblaster. All screened compounds were filtered through Lipinski’s rules and other properties. PyRx tool was then implemented to dock selected compounds. Finally, ligand ZINC48251687 re-docked using Autodock 4.2 with His 383, His 387 and Glu 411 as flexible residues of tACE. Molecular Dynamics simulation was then carried out to investigate the binding stability of the screened ligand in a dynamic environment. It has been observed that tACE-ligand complex was quite stable over the entire simulation run. We found that ligand was stabilized by strong hydrogen bonding interactions with Ala 354, Ala 356, Tyr 523 and Zn2+ of tACE. Thus, ZINC48251687 could be used as starting point for the development of new non-peptidic inhibitor of tACE and for designing drug against cardiovascular and related renal diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Peptide Research and Therapeutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
